Preliminary results from the phase 1/2 BEACON trial of BEAM-101 showed evidence that the drug was able to normalise markers of haemolysis – the red blood cell destruction that is a feature of ...

The flavonoid silymarin and one of its structural components, silibinin, are substances with documented hepatoprotective properties. Their mechanisms of action are still poorly understood. However ...

which showed that crovalimab was as effective as Soliris at controlling the destruction of red blood cells (haemolysis) that characterises PNH, whilst also reducing the need for blood transfusions.

The results of most clinical trials with the thistle (Silybum marianum) extract, silymarin, are difficult to interpret because of a variety of reasons: small sample size, variability in type and ...